Current Report Filing (8-k)
14 March 2023 - 12:30AM
Edgar (US Regulatory)
0001814114
false
0001814114
2023-03-13
2023-03-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 13, 2023
ORCHESTRA BIOMED HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-39421 |
|
92-2038755 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
150 Union Square Drive
New Hope, Pennsylvania 18938
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (215) 862-5797
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, par value $0.0001 per share |
|
OBIO |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
A copy of a slide presentation that Orchestra
BioMed Holdings, Inc. (the “Company”) uses at investor and industry conferences and presentations is attached to this Current
Report on Form 8-K (“Current Report”) as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure.
Additionally, the Company has posted the slide presentation on its website at https://investors.orchestrabiomed.com under the Investor
Relations section.
The information in Item 7.01 of this Current Report,
including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.
The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.
Item 8.01 Other Events.
The Company considers its exposure to
Silicon Valley Bank (“SVB”) as de minimis, given that less than one percent of its total cash, cash
equivalents and marketable securities are held at SVB.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ORCHESTRA BIOMED HOLDINGS, INC. |
|
|
|
|
By: |
/s/ David P. Hochman |
|
Name: |
David P. Hochman |
|
Title: |
Chief Executive Officer |
Date: March 13, 2023
Health Sciences Acquisit... (NASDAQ:HSAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Health Sciences Acquisit... (NASDAQ:HSAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024